Coppell Advisory Solutions’s NovoCure NVCR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$369K Sell
23,080
-15,873
-41% -$265K 0.04% 244
2026
Q2
$4.86M Buy
+38,953
New +$589K 0.4% 50
2025
Q1
– Sell
-76
Closed -$2.29K – 1343
2024
Q4
$2.29K Sell
76
-1,048
-93% -$22.2K ﹤0.01% 1512
2024
Q3
$17.5K Buy
1,124
+214
+24% +$3.88K ﹤0.01% 917
2024
Q2
$15.6K Buy
+910
New +$16K ﹤0.01% 873

Other funds holding NVCR

Coppell Advisory Solutions's NVCR Position: Q3 2026 in Review

Coppell Advisory Solutions reduced its NovoCure (NVCR) stake by 41% in Q3 2026, selling an estimated $265K and leaving 23,080 shares worth $369K. The position accounts for 0.04% of the portfolio, ranked #244.

Coppell Advisory Solutions first reported a position in NVCR in Q2 2024 and has held it in 5 quarters since. The position peaked at $4.86M in Q2 2026. 242 funds tracked by Wall St. Rank hold NVCR as of Q3 2026.

  • Coppell Advisory Solutions held 23,080 shares of NovoCure worth $369K as of Q3 2026.
  • Coppell Advisory Solutions sold 15,873 NovoCure shares in Q3 2026, an estimated $265K.
  • NovoCure made up 0.04% of Coppell Advisory Solutions's portfolio in Q3 2026, its #244 holding.
  • Coppell Advisory Solutions first reported a position in NovoCure in Q2 2024 and has held it in 5 quarters since.
  • Coppell Advisory Solutions's NovoCure position peaked at $4.86M in Q2 2026.
  • 242 funds tracked by Wall St. Rank held NovoCure as of Q3 2026.

Based on Coppell Advisory Solutions's 13F filing for Q3 2026, filed 16 Nov 2026.